ArticleBMC complementary and alternative medicine2014
Cytotoxic and antioxidant properties of active principals isolated from water hyacinth against four cancer cells lines.
Article in BMC complementary and alternative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Nicotiana glauca leaf extract exhibits synergistic antioxidant and anticancer activities revealed by phytochemical profiling and molecular docking.Scientific reports · 2026Article
- GC-MS profiling, biological activities and molecular docking of total sterol extracts from Pontederia crassipes (Lake Tana, Ethiopia).Scientific reports · 2026Article
- Article
- First Time Isolation Report of Bioactive Flavonoids From Water Hyacinth (Eichhornia crassipes) Flower Associated With Pharmacological Investigation.BioMed research international · 2026Article
- Fly ash pollution causes morpho-anatomical and biochemical changes in Eichhornia crassipes (Mart.) Solms and Pistia stratiotes L: demonstrating stress-tolerant activity.Scientific reports · 2025Article
- Quorum sensing inhibition by South African medicinal plants species: an in vitro and an untargeted metabolomics study.BMC complementary medicine and therapies · 2025Article
- Article
- Article
- Article
- Streptococcosis a Re-Emerging Disease in Aquaculture: Significance and Phytotherapy.Animals : an open access journal from MDPI · 2022Review
- Review
- Article
- Chemical Structure and Biological Activities of Secondary Metabolites fromMolecules (Basel, Switzerland) · 2021Review
- Evaluation of antioxidant and anticancer activity of crude extract and different fractions of Chlorella vulgaris axenic culture grown under various concentrations of copper ions.BMC complementary medicine and therapies · 2021Article
- Botanicals from the leaves ofHeliyon · 2020Article
- Remedial potential of bacterial and fungal strains (Bacillus subtilis, Aspergillus niger, Aspergillus flavus and Penicillium chrysogenum) against organochlorine insecticide Endosulfan.Folia microbiologica · 2020Article
- Review
- Structural andEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Potential of Central, Eastern and Western Africa Medicinal Plants for Cancer Therapy: Spotlight on Resistant Cells and Molecular Targets.Frontiers in pharmacology · 2017Review
- Chemical Profile, Antioxidant and Antibacterial Activities of Achillea moschata Wulfen, an Endemic Species from the Alps.Molecules (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEichhornia crassipes (Mart) solms is an invasive macrophyte causing serious problems to the network of irrigation and drainage canals in the Nile Delta region. The present study aim to evaluate the potential anticancer and antioxidant activities of Eichhornia crassipes crude extract and its pure compounds.
methodsThe macrophyte was collected from El-Zomor canal, River Nile (Egypt), cleaned, air dried, grinded then extracted with methanol (crude extract). The extract was fractionated using pre-coated silica gel plates (TLC F254) with hexane/ethyl acetate (8.5: 1.5 v/v) as mobile phase. Nine fractions were separated (A-I) then scratched, eluted with the same mobile phase, filtered and the separated fractions were determined and identified using spectroscopic methods (Mass spectrum (MS), Infra red (IR) and Proton H-Nuclear magnetic resonance (H-NMR). Both the crude extract and its nine identified compounds were tested for their antioxidant (using 2, 2 diphenyl-1-picrylhydrazyl (DPPH), 2, 2'- azino-bis {ethylbenzthiazoline-6-sulfonic acid (ABTS.)} methods) and anticancer activity (using MCF-7, HeLa, Hep.G2 and EACC cell lines).
resultsThe antioxidant and anticancer activities of the crude extract exhibited the highest effect while the compounds showed variable effects which depend on the type of compound and cancer cell line. The antioxidant activity of the crude extract exhibited the highest followed in descending order by compounds D, E, G and H respectively. Concerning the anticancer potency, the crude extract showed also the highest effect while the identified compounds (A, B, C, D, E, F, G, H and I) showed variable anticancer activities against the four different cell lines. In addition, Compound I exhibited the most potent anticancer activity against HepG2 cell line while compound D exhibited high anticancer activity against HeLa cells and EACC. The results revealed the presence of different compounds (Alkaloids and terpenoids) with variable antioxidant and anticancer activities which elicited an auto-augmentation in the crude extract leading to its greatest activities. The action of the identified anticancer compounds on DNA fragmentation was studied.
conclusionThe study illustrated the potential of Eichhornia as a valuable resource for natural compounds of desirable medicinal properties (e.g. antioxidants and anticancer).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.